| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
ATM 1.0 nM (IC50)
|
|---|---|
| ln Vitro |
In SW620 and HCT116 cells, A011(compound 8d)(10, 30, 100 nM; 5 days) enhances the sensitivity to CPT-11(100 nM)[1]. When coupled with CPT-11, A011 (0-100 nM; 24, 72 h) can cause cell apoptosis and cell cycle arrest in the G2/M phase [1]. Under 1.5 or 3 Gy irradiation, A011(3, 9, 27, 83, 250 nM) dose-dependently lowers the expression of p-ATM and p-Chk2 in SW620 cells[1].
|
| ln Vivo |
In mice, A011 (5 mg/kg; intraperitoneal injection; once daily for 23 days) and CPT-11 (5 mg/kg; intraperitoneal injection; once weekly) had anticancer efficacy [1].
|
| Cell Assay |
Cell Proliferation Assay[1]
Cell Types: SW620, HCT116 cells Tested Concentrations: 10, 30, 100 nM Incubation Duration: 5 days Experimental Results: Increased the sensitivity of SW620 and HCT116 cells to CPT-11(100 nM). Cell Cycle Analysis[1] Cell Types: SW620, HCT116 cells Tested Concentrations: 0-100 nM Incubation Duration: 24 h Experimental Results: Dose-dependent increased in G2/M arrest was noted when A011 was combined with CPT-11 in SW620 and HCT116 cells. Apoptosis Analysis[1] Cell Types: SW620, HCT116 cells Tested Concentrations: 0-100 nM Incubation Duration: 72 h Experimental Results: Dramatically increased the apoptotic cell populations when combined with CPT-11. Western Blot Analysis[1] Cell Types: SW620, HCT116 cells Tested Concentrations: 3, 10, 30 nM Incubation Duration: 24 h Experimental Results: decreased the expression of p-Chk2 when combined with CPT-11. |
| Animal Protocol |
Animal/Disease Models: Female nude mice (SW620 tumor xenograft model)[1]
Doses: 5 mg/kg; CPT-11 (5 mg/kg, ip; once a week) Route of Administration: Ip; one time/day for 23 days Experimental Results: Increased the antitumor activity of CPT-11. |
| References |
| Molecular Formula |
C27H28N6O
|
|---|---|
| Molecular Weight |
452.55
|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2097 mL | 11.0485 mL | 22.0970 mL | |
| 5 mM | 0.4419 mL | 2.2097 mL | 4.4194 mL | |
| 10 mM | 0.2210 mL | 1.1049 mL | 2.2097 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
